Premium
Combination therapy for multidrug‐resistant cytomegalovirus disease
Author(s) -
Stuehler C.,
Stüssi G.,
Halter J.,
Nowakowska J.,
Schibli A.,
Battegay M.,
Dirks J.,
Passweg J.,
Heim D.,
Rovo A.,
Kalberer C.,
Bucher C.,
Weisser M.,
Dumoulin A.,
Hirsch H.H.,
Khan.
Publication year - 2015
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12435
Subject(s) - medicine , foscarnet , cidofovir , ganciclovir , cytomegalovirus , hematopoietic stem cell transplantation , artesunate , transplantation , combination therapy , immunology , multiple drug resistance , virology , human cytomegalovirus , drug resistance , viral disease , virus , herpesviridae , plasmodium falciparum , malaria , microbiology and biotechnology , biology
Multidrug‐resistant ( MDR ) cytomegalovirus ( CMV ) emerged after transient responses to ganciclovir, foscarnet, and cidofovir in a CMV ‐seropositive recipient who underwent allogeneic hematopoietic stem cell transplantation from a CMV ‐seronegative donor. Experimental treatments using leflunomide and artesunate failed. Re‐transplantation from a CMV ‐seropositive donor supported by adoptive transfer of pp65‐specific T cells and maribavir was followed by lasting suppression. This case illustrates that successful MDR CMV therapy may require individualized multidisciplinary approaches.